世界の重症筋無力症診断と治療市場調査と予測

当レポートでは、世界の重症筋無力症診断と治療市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 レポートのサマリー

第2章 市場概要と洞察

• 定義
• アナリストの見解と現在の市場動向
• 法規制

第3章 市場決定因子

• 促進因子
  • 感染症の罹患率上昇
  • 腫瘍学における幅広い応用
  • FDAが認可した検査数の増加
  • 正確かつ費用対効果の高い診断ソリューションの需要拡大
• 阻害因子
  • 法規制の課題とハードル
  • 途上国における医療インフラの不足
• 機会
  • 個別化治療の需要拡大
  • シーケンシングとポイントオブケア検査デバイスの技術進歩

第4章 市場セグメンテーション

• 技術別
  • ポリメラーゼ連鎖反応
  • in situハイブリッド化
  • 質量分析
  • DNAマイクロアレイ
  • 次世代シーケンシング
  • 転写媒介増幅
  • 等温核酸増幅
• 製品別
  • 検査機器
  • 診断試薬・キット
• 用途別
  • 感染症
  • 癌
  • 心血管疾患
  • 遺伝子検査
  • 法医学検査
  • 神経疾患
  • その他
• エンドユーザー別
  • 病院
  • 診断センター
  • 研究機関

第5章 競合環境

• 戦略分析
• 主要企業分析

第6章 地域別分析

• 北米
• 欧州
• アジア太平洋地域
• その他の諸国

第7章 企業プロファイル

• Abbott Laboratories, Inc.
• Agilent Technologies, Inc.
• AltheaDX, Inc.
• AutoGenomics, Inc.
• Beckman Coulter, Inc.
• Becton Dickinson and Co.
• Biocartis N.V.
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• CareDX, Inc.
• Danaher Corp.
• ELITech Group
• F. Hoffmann-La Roche, Ltd.
• Genetic Technologies, Ltd.
• GenMark Diagnostics, Inc.
• Genomic Health, Inc.
• Grifols, S.A.
• Hologic, Inc.
• HTG Molecular Diagnostics, Inc.
• MDxHealth Group
• Merck KGaA
• Oxford Nanopore Technologies Ltd.
• QIAGEN N.V.
• Sequenom Laboratories
• Siemens AG
• Source BioScience UK Limited
• Thermo Fisher Scientific, Inc.
• Veracyte, Inc.

List of Tables

• TABLE # 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
• TABLE # 2 GLOBAL POLYMERASE CHAIN REACTION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 3 GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 4 GLOBAL MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 5 GLOBAL DNA MICROARRAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 6 GLOBAL NEXT GENERATION SEQUENCING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 7 GLOBAL TRANSCRIPTION MEDIATED AMPLIFICATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 8 GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 9 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023 ($ MILLION)
• TABLE # 10 GLOBAL DIAGNOSTIC REAGENTS AND KITS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 11 GLOBAL TESTING EQUIPMENT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 12 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION ,2017-2023 ($ MILLION)
• TABLE # 13 GLOBAL INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 14 GLOBAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 15 GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 16 GLOBAL FORENSIC SCIENCE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 17 GLOBAL CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 18 GLOBAL NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 19 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 20 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY END-USER ,2017-2023 ($ MILLION)
• TABLE # 21 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 22 GLOBAL RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 23 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
• TABLE # 24 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023 ($ MILLION)
• TABLE # 25 NORTH AMERICAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
• TABLE # 26 NORTH AMERICAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
• TABLE # 27 NORTH AMERICAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
• TABLE # 28 NORTH AMERICAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
• TABLE # 29 NORTH AMERICAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
• TABLE # 30 EUROPEAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
• TABLE # 31 EUROPEAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
• TABLE # 32 EUROPEAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
• TABLE # 33 EUROPEAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
• TABLE # 34 EUROPEAN MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
• TABLE # 35 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
• TABLE # 36 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
• TABLE # 37 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
• TABLE # 38 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
• TABLE # 39 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
• TABLE # 40 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
• TABLE # 41 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
• TABLE # 42 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
• TABLE # 43 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)

List of Figures

• FIGURE # 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE BY TECHNOLOGY, 2017 VS 2023 (%)
• FIGURE # 2 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE BY PRODUCT, 2017 VS 2023 (%)
• FIGURE # 3 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE BY APPLICATION, 22017 VS 2023 (%)
• FIGURE # 4 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE BY END-USER, 2017 VS 2023 (%)
• FIGURE # 5 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
• FIGURE # 6 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 7 UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 8 CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 9 EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 10 UK MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 11 GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 12 SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 13 FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 14 ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 15 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 16 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 17 INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 18 CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 19 JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 20 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
• FIGURE # 21 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)

Myasthenia gravis is a chronic autoimmune disorder in which the person loses control over voluntary muscles. A person with such disease might not be able to breathe properly, lift objects and do activities that require voluntary muscle. The condition arises due to the error in transmission of impulses to muscles, the human body produces antibodies due to immune disorder which affects the healthy tissue. The neuromuscular junction is damaged thereby reducing the effect of neurotransmitter acetylcholine which facilitates the communication between nerve cells and muscles. The rise in geriatric population contributes significantly to the growth of this market as the person above 60 is more prone to such diseases. The government approval for use of monoclonal antibodies for treatment is yet another contributing factor in the growth of the market. The stressful lifestyle of individual and exposure to heat may also lead to myasthenia gravis. The major factor restraining the growth of the market is the high cost of drugs and the significant side effects of immunosuppressant drugs. The research and development in novel drug development will drive the future market for myasthenia gravis drugs.

The market is divided into North America, Europe, Asia-Pacific and Rest of the World. North America has the largest market for myasthenia gravis attributed to the presence of a large number of patients in the region. According to myasthenia gravis foundation of America, 20 people out of 100000 suffers from the disease in the US. The region also has the most advanced healthcare infrastructure which is driving the technological advancement in the market. The UK in the European region holds the second place in prevalence ranking after the US, the region also has the well-developed infrastructure for healthcare. The Asia-Pacific region will grow significantly due to the increase in expenditure for procurement of better healthcare infrastructure in near future.

The competition in myasthenia gravis market is tough due to the presence of a large number of market player. The market players are engaged in providing various type of drugs and plasma therapies for the treatment of diseases. Additionally, R&D in the field of novel drugs such as monoclonal antibodies is also the boon for the entire mankind. The key players in the global myasthenia gravis market are Alexion Pharmaceuticals, Inc., Argenx SE, Avadel Pharmaceutical PLC, Catalyst Pharmaceuticals, Inc., CSL Behring, Curavac, Inc, and Cytokinetics, Inc. The companies are engaged in rapid research and development for the development of effective treatment measure for the disease.

Research methodology

The market study of global myasthenia gravis market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

• Financial reports of companies involved in the market

• Authentic Public Databases such as Myasthenia Gravis Foundation (MGF) and Muscular Dystrophy Association (MDA).

• Whitepapers such as research papers and news blogs

• Company websites and their product catalog.

The report is intended for pharmaceutical companies and researchers in the market, investing companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market segmentation

Global myasthenia gravis market is segmented on the basis of various regions and below mentioned segments:

• 1. Global Myasthenia Gravis Market Research and Analysis by Diagnosis

• 2. Global Myasthenia Gravis Market Research and Analysis by Treatment

• 3. Global Myasthenia Gravis Market Research and Analysis by End-User

The report covers:

• Comprehensive research methodology of the global myasthenia gravis market.

• This report also includes a detailed and extensive market overview with key analyst insights.

• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

• Analysis of regional regulations and other government policies impacting the global myasthenia gravis market.

• Insights about market determinants which are stimulating the global myasthenia gravis market.

• Detailed and extensive market segments with regional distribution of forecast revenues.

• Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
• 1.2.1. By Segments
• 1.2.2. By Geography
• 1.2.3. By Stakeholders

2. Market Overview and Insights

• 2.1. Definition
• 2.2. Analyst Insights & Current Market Trends
• 2.2.1. Key Findings
• 2.2.2. Recommendations
• 2.2.3. Conclusion
• 2.3. Regulation

3. Market Determinants

• 3.1. Motivators
• 3.1.1. Rising Prevalence of Infectious Diseases
• 3.1.2. Extensive Application in Oncology
• 3.1.3. Growing Number of FDA-Cleared and Approved Tests
• 3.1.4. Growing Demand for Accurate and Cost-Effective Diagnostic Solutions
• 3.2. Restraints
• 3.2.1. Regulatory Issues and Hurdles
• 3.2.2. Lack of Medical Infrastructure in Developing and Under Developed Countries
• 3.3. Opportunities
• 3.3.1. Growing Demand for Personalized Treatment
• 3.3.2. Technological Advancement in Sequencing and Point of Care Testing Devices

4. Market Segmentation

• 4.1. Global Molecular Diagnostics Market by Technology
• 4.1.1. Polymerase Chain Reaction (PCR)
• 4.1.2. In Situ Hybridization (ISH)
• 4.1.3. Mass Spectrometry (MS)
• 4.1.4. DNA Microarray
• 4.1.5. Next-Generation Sequencing (NGS)
• 4.1.6. Transcription Mediated Amplification
• 4.1.7. Isothermal Nucleic Acid Amplification
• 4.2. Global Molecular Diagnostics Market by Product
• 4.2.1. Testing instruments
• 4.2.2. Diagnostic Reagents and Kits
• 4.3. Global Molecular Diagnostics Market by Application
• 4.3.1. Infectious Diseases
• 4.3.2. Cancer
• 4.3.3. Cardiovascular Disease
• 4.3.4. Genetic Testing
• 4.3.5. Forensic Science
• 4.3.6. Neurological Disease
• 4.3.7. Other (Microbiology)
• 4.4. Global Molecular Diagnostics Market by End-User
• 4.4.1. Hospitals
• 4.4.2. Diagnostic Centres
• 4.4.3. Research Institute

5. Competitive Landscape

• 5.1. Key Strategies
• 5.2. Key Company Analysis

6. Regional Analysis

• 6.1. North America
• 6.1.1. United States
• 6.1.2. Canada
• 6.2. Europe
• 6.2.1. UK
• 6.2.2. Germany
• 6.2.3. Spain
• 6.2.4. France
• 6.2.5. Italy
• 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
• 6.3.1. China
• 6.3.2. Japan
• 6.3.3. India
• 6.3.4. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Abbott Laboratories, Inc.
• 7.2. Agilent Technologies, Inc.
• 7.3. AltheaDX, Inc.
• 7.4. AutoGenomics, Inc.
• 7.5. Beckman Coulter, Inc.
• 7.6. Becton Dickinson and Co.
• 7.7. Biocartis N.V.
• 7.8. bioMerieux S.A.
• 7.9. Bio-Rad Laboratories, Inc.
• 7.10. CareDX, Inc.
• 7.11. Danaher Corp.
• 7.12. ELITech Group
• 7.13. F. Hoffmann-La Roche, Ltd.
• 7.14. Genetic Technologies, Ltd.
• 7.15. GenMark Diagnostics, Inc.
• 7.16. Genomic Health, Inc.
• 7.17. Grifols, S.A.
• 7.18. Hologic, Inc.
• 7.19. HTG Molecular Diagnostics, Inc.
• 7.20. MDxHealth Group
• 7.21. Merck KGaA
• 7.22. Oxford Nanopore Technologies Ltd.
• 7.23. QIAGEN N.V.
• 7.24. Sequenom Laboratories
• 7.25. Siemens AG
• 7.26. Source BioScience UK Limited
• 7.27. Thermo Fisher Scientific, Inc.
• 7.28. Veracyte, Inc.